Everything below concerns synthetic peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-02-01. Numbers and descriptions here follow the published literature rather than marketing material.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
On December 4, 2020, Pritzker announced that Illinois would receive 109,000 initial doses of Pfizer's COVID-19 vaccine once the U.S. Food and Drug Administration approved the vaccine. On February 26, 2021, Pritzker, Cook County Board president Toni Preckwinkle, Chicago mayor Lori Lightfoot, U.S. senators Dick Durbin and Tammy Duckworth, and the Biden administration announced that eligible Illinoisans could get vaccinated starting March 10 at a new mass vaccination site at the United Center. On July 29, 2021, Pritzker announced that everyone who enters a state building was required to wear a face mask regardless of vaccination status. On August 5, 2021, Pritzker announced that face masks must be worn at all times while inside P-12 schools, daycares, and long-term care facilities regardless of vaccination status. He also announced that face masks were required for all P-12 indoor sports, and that all state employees in congregate facilities must be vaccinated by October 4. On August 26, 2021, Pritzker announced that beginning on August 30, a statewide indoor mask mandate would be reimposed to handle the surge caused by the Delta variant. He also announced a vaccine mandate for all education employees in P-12 and higher education statewide and for all higher education students and healthcare workers. Pritzker announced that anyone who did not get a COVID-19 vaccine by September 5 would have to do weekly COVID testing. On September 19, 2021, Pritzker began imposing a COVID-19 vaccine mandate for college students, educators and most health care workers.
In December 2013, NSF launched a lawsuit against MusclePharm and declared that MusclePharm is not authorized to use any NSF certification marks, to claim that any of its products are certified by NSF, or to claim that they have been manufactured in an NSF GMP certified or registered facility. The Tawnsaura Group sued MusclePharm for patent infringement. 2011 Environmental Research Center (ERC) filed a notice of intent to start litigation against over 200 nutrition and supplement companies, including MusclePharm, alleging violations of California Proposition 65. I'm a lawsuit, ThermoLife claimed that MusclePharm infringed ThermoLife's patent on amino acid compounds including creatine nitrate. 2006 MusclePharm was first incorporated.
=== Oxytalan fibers === Oxytalan fibers are unique to the PDL and are elastic in nature. It inserts into cementum and runs in two directions: parallel to root surface and oblique to root surface. The function is thought to maintain the patency of blood vessels during occlusal loading. Further research is needed to determine the function of oxytalan fibers.
Binds to the progesterone receptor (PR) and to an unidentified membrane receptor that drives Prostaglandin E2 (PGE₂) synthesis via COX-2 induction. Induces a feed-forward loop in which PGE₂ amplifies BMP2 expression, accelerating osteogenic and chondrogenic differentiation. Causes sustained phosphorylation of PKCε, an isoform linked to suppression of the hypertrophic cartilage marker MATN1 and to formation of articular-cartilage (interzone) phenotypes. Pharmacological blockade of either PR (mifepristone) or COX-2 (indomethacin) abolishes these effects, confirming that stanozolol’s osteochondral activity requires simultaneous PR signaling and PGE₂-driven crosstalk with the BMP2 pathway. Additionally, stanozolol has been shown to exert activity via estrogen receptor alpha (ERα) in vivo. In a rat model of GnRH agonist-induced growth plate suppression, stanozolol restored chondrocyte proliferation via ERα activation, indicating selective estrogen receptor-mediated effects in growth plate cartilage.
The 3rd Marine Division and a regiment from the ARVN 1st Division launch Operation Maine Crag in the "Vietnam Salient" of Quảng Trị Province. The operation uncovered large amounts of supplies and resulted in 207 PAVN killed.
Sources: en.wikipedia.org
Sample acquisition: the most commonly used samples for metagenomic sequencing are blood, stool, cerebrospinal fluid (CSF), urine, or nasopharyngeal swabs. Among these, blood and CSF are the cleanest, having less background noise, while the others are expected to have a great amount of commensals and/or opportunistic infections and thus have more background noise. Samples should be collected with much caution as surgical specimens could be contaminated during handling of the biopsy; for example, lumbar punctures to obtain CSF specimens may be contaminated during the procedure. RNA/DNA extraction: the DNA and the RNA of the sample is extracted by using an extraction kit. If there is a strong previous suspicion of the pathogen genome composition and since the amount of pathogen nucleic acid in more noise samples is overwhelmed by the RNA/DNA of other organisms, selecting an extraction kit of only RNA or DNA would be a more specific and convenient approach. Some commerciable available kits are for example RNeasy PowerSoil Total RNA kit (Qiagen), RNeasy Minikit (Qiagen), MagMAX Viral Isolation kit (ABI), Viral RNA Minikit (Qiagen). Optimization strategies for library preparation: because of high levels of background noise in metagenomic sequencing, several target enrichment procedures have been developed that aim to increase the probability of capturing pathogen-derived transcripts and/or genomes. Generally there are two main approaches that can be used to increase the amount of pathogen signal in a sample: negative selection and positive enrichment.
1,1'-Carbonyldiimidazole (CDI) is an organic compound with the molecular formula (C3H3N2)2CO. It is a white crystalline solid. It is often used for the coupling of amino acids for peptide synthesis and as a reagent in organic synthesis.
=== Withdrawal === Discontinuation of alcohol after extended heavy use and associated tolerance development (resulting in dependence) can result in alcohol withdrawal. Alcohol is one of the most dangerous drugs to withdraw from. Alcohol withdrawal can cause confusion, paranoia, anxiety, insomnia, agitation, tremors, fever, nausea, vomiting, autonomic dysfunction, seizures, and hallucinations. In severe cases, death can result. Delirium tremens is a condition that develops in some cases of severe withdrawal, with onset typically 48–72 hours after discontinuation. It is considered a medical emergency and should be treated in an inpatient or intensive care unit.
== Medical uses == Dexrazoxane has been used to protect the heart against the cardiotoxic side effects of chemotherapeutic drugs such as anthracyclines, such as daunorubicin or doxorubicin or other chemotherapeutic agents. However, in July 2011 the European Medicines Agency (EMA) released a statement restricting use only in adult patients with cancer who have received > 300 mg/m2 doxorubicin or > 540 mg/m2 epirubicin and general approval for use for cardioprotection. That showed a possibly higher rate of secondary malignancies and acute myelogenous leukemia in pediatric patients treated for different cancers with both dexrazoxane and other chemotherapeutic agents that are associated with secondary malignancies. On 19 July 2017, based on evaluation of the currently available data the European Commission issued an EU-wide legally binding decision to implement the recommendations of the Committee for Medicinal Products for Human Use (CHMP) on dexrazoxane and lifted its 2011-contraindication for primary prevention of anthracycline-induced cardiotoxicity with dexrazoxane in children and adolescents where high doses (≥ 300 mg/m3) of anthracyclines are anticipated. Dexrazoxane was designated by the US FDA as an orphan drug for "prevention of cardiomyopathy for children and adults 0 through 16 years of age treated with anthracyclines". This decision allows virtually all children to receive dexrazoxane starting with the first dose of anthracycline at the discretion of the treating provider.
=== Serotonylation === Protein serotonylation refers to the post-translational modification in which serotonin is covalently attached to glutamine residues on substrate proteins via a transamidation reaction catalyzed by TGM2. Serotonylation is a type of monoaminylation, which itself refers to the overall class of post-translational modifications involving monoamines. However, monoaminylation reactions are further classified by the individual monoamine reactant they describe (ie., serotonylation, dopaminylation, histaminylation). Serotonylation has been reported for both histone and non-histone protein substrates, and thus represents a distinct neuroepigenetic and neuroproteomic regulatory mechanism with various implications in health and disease. Since 2003, multiple studies have revealed the critical role of serotonylation in mediating a wide range of physiological processes, both in the nervous system and beyond. Serotonylation is known to contribute to several significant diseases, including neuropsychiatric disorders such as depression and schizophrenia, as well as a variety of cancers. To date, notable protein serotonylation substrates include several metabolic enzymes (GAPDH, mTOR), Rab GTPases (Rab3a, Rab27a), Rho GTPases (RhoA, Rac1, Cdc42), proteins involved in muscle contractility (⍺-actinin, SERCA2a), extracellular matrix proteins (fibronectin), neural surface proteins, and Ras, as well as histone H3.
Sources: en.wikipedia.org
Although the preponderance of evidence is on the side of a multidimensional measure, the issue has not been fully resolved owing in part to limitations in the methodological knowledge available on distinguishing between substantive and method variance.
==== Diabetes ==== The high doses of nicotinic acid used to treat hyperlipidemia have been shown to elevate fasting blood glucose in people with type 2 diabetes. Long-term nicotinic acid therapy was also associated with an increase in the risk of new-onset type 2 diabetes.
=== Motility assays === Agarose is sometimes used instead of agar to measure microorganism motility and mobility. Motile species will be able to migrate, albeit slowly, throughout the porous gel and infiltration rates can then be visualized. The gel's porosity is directly related to the concentration of agar or agarose in the medium, so different concentration gels may be used to assess a cell's swimming, swarming, gliding and twitching motility. Under-agarose cell migration assay may be used to measure chemotaxis and chemokinesis. A layer of agarose gel is placed between a cell population and a chemoattractant. As a concentration gradient develops from the diffusion of the chemoattractant into the gel, various cell populations requiring different stimulation levels to migrate can then be visualized over time using microphotography as they tunnel upward through the gel against gravity along the gradient.
=== As an enzyme for catalytic activity === Cytochrome c has also been widely studied as an enzyme with peroxidase-like activity. Cytochrome c was conjugated to charged polymer to test its peroxidase-like activity. Inspired from natural examples of enzyme encapsulation in protein-based cage structures (Example: Carboxysomes, ferritin, and encapsulin), Cytochrome c was encapsulated in a 9 nm small self-assembling DNA binding protein from nutrient starved cells (Dps) protein cage using chimeric self-assembly approach. Authors observed unique catalytic activity behavior upon encapsulating enzyme inside a protein-cage, which was different from enzyme in solution. This was attributed to local microenvironment provided by Dps nanocage's interior cavity which is different than bulk.
=== EC 1.3.1 With NAD+ or NADP+ as acceptor === EC 1.3.1.1: dihydrouracil dehydrogenase (NAD+) EC 1.3.1.2: dihydropyrimidine dehydrogenase (NADP+) EC 1.3.1.3: Δ4-3-oxosteroid 5β-reductase EC 1.3.1.4: transferred to EC 1.3.1.22, 3-oxo-5α-steroid 4-dehydrogenase (NADP+) EC 1.3.1.5: cucurbitacin Δ23-reductase EC 1.3.1.6: fumarate reductase (NADH) EC 1.3.1.7: meso-tartrate dehydrogenase EC 1.3.1.8: acyl-CoA dehydrogenase (NADP+) EC 1.3.1.9: enoyl-[acyl-carrier-protein] reductase (NADH) EC 1.3.1.10: enoyl-[acyl-carrier-protein] reductase (NADPH, Si-specific) EC 1.3.1.11: 2-coumarate reductase EC 1.3.1.12: prephenate dehydrogenase EC 1.3.1.13: prephenate dehydrogenase (NADP+) EC 1.3.1.14: dihydroorotate dehydrogenase (NAD+) EC 1.3.1.15: dihydroorotate dehydrogenase (NADP+) EC 1.3.1.16: β-nitroacrylate reductase EC 1.3.1.17: 3-methyleneoxindole reductase EC 1.3.1.18: kynurenate-7,8-dihydrodiol dehydrogenase EC 1.3.1.19: cis-1,2-dihydrobenzene-1,2-diol dehydrogenase EC 1.3.1.20: trans-1,2-dihydrobenzene-1,2-diol dehydrogenase EC 1.3.1.21: 7-dehydrocholesterol reductase EC 1.3.1.22: 3-oxo-5α-steroid 4-dehydrogenase (NADP+) EC 1.3.1.23: Identical to EC 1.3.1.3, Δ4-3-oxosteroid 5β-reductase EC 1.3.1.24: biliverdin reductase EC 1.3.1.25: 1,6-dihydroxycyclohexa-2,4-diene-1-carboxylate dehydrogenase EC 1.3.1.26: Now EC 1.17.1.8, 4-hydroxy-tetrahydrodipicolinate reductase EC 1.3.1.27: 2-hexadecenal reductase EC 1.3.1.28: 2,3-dihydro-2,3-dihydroxybenzoate dehydrogenase EC 1.3.1.29: cis-1,2-dihydro-1,2-dihydroxynaphthalene dehydrogenase EC 1.3.1.30: transferred to EC 1.3.1.22, 3-oxo-5α-steroid 4-dehydrogenase (NADP+) EC 1.3.1.31: 2-enoate reductase EC 1.3.1.32: maleylacetate reductase EC 1.3.1.33: protochlorophyllide reductase EC 1.3.1.34: 2,4 Dienoyl-CoA reductase (NADPH) EC 1.3.1.35: Now EC 1.14.19.22, microsomal oleoyl-lipid 12-desaturase EC 1.3.1.36: geissoschizine dehydrogenase EC 1.3.1.37: cis-2-enoyl-CoA reductase (NADPH) EC 1.3.1.38: trans-2-enoyl-CoA reductase (NADPH) EC 1.3.1.39: trans-2-enoyl-CoA reductase (NADPH) EC 1.3.1.40: 2-hydroxy-6-oxo-6-phenylhexa-2,4-dienoate reductase EC 1.3.1.41: xanthommatin reductase EC 1.3.1.42: 12-oxophytodienoate reductase EC 1.3.1.43: arogenate dehydrogenase EC 1.3.1.44: trans-2-enoyl-CoA reductase (NAD+) EC 1.3.1.45: 2′-hydroxyisoflavone reductase EC 1.3.1.46: biochanin-A reductase EC 1.3.1.47: α-santonin 1,2-reductase EC 1.3.1.48: 13,14-dehydro-15-oxoprostaglandin 13-reductase EC 1.3.1.49: cis-3,4-dihydrophenanthrene-3,4-diol dehydrogenase EC 1.3.1.50: n Now EC 1.1.1.252 tetrahydroxynaphthalene reductase EC 1.3.1.51: 2′-hydroxydaidzein reductase EC 1.3.1.52: Now EC 1.3.8.5, 2-methyl-branched-chain-enoyl-CoA reductase EC 1.3.1.53: (3S,4R)-3,4-dihydroxycyclohexa-1,5-diene-1,4-dicarboxylate dehydrogenase EC 1.3.1.54: precorrin-6A reductase EC 1.3.1.55: identical to EC 1.3.1.25, 1,6-dihydroxycyclohexa-2,4-diene-1-carboxylate dehydrogenase EC 1.3.1.56: cis-2,3-dihydrobiphenyl-2,3-diol dehydrogenase EC 1.3.1.57: phloroglucinol reductase EC 1.3.1.58: 2,3-dihydroxy-2,3-dihydro-p-cumate dehydrogenase EC 1.3.1.59: There is no evidence that the enzyme exists EC 1.3.1.60: dibenzothiophene dihydrodiol dehydrogenase EC 1.3.1.61: identical to EC 1.3.1.53, (3S,4R)-3,4-dihydroxycyclohexa-1,5-diene-1,4-dicarboxylate dehydrogenase EC 1.3.1.62: pimeloyl-CoA dehydrogenase EC 1.3.1.63: Now EC 1.21.1.2, 2,4-dichlorobenzoyl-CoA reductase EC 1.3.1.64: phthalate 4,5-cis-dihydrodiol dehydrogenase EC 1.3.1.65: 5,6-dihydroxy-3-methyl-2-oxo-1,2,5,6-tetrahydroquinoline dehydrogenase EC 1.3.1.66: cis-dihydroethylcatechol dehydrogenase EC 1.3.1.67: cis-1,2-dihydroxy-4-methylcyclohexa-3,5-diene-1-carboxylate dehydrogenase EC 1.3.1.68: 1,2-dihydroxy-6-methylcyclohexa-3,5-dienecarboxylate dehydrogenase EC 1.3.1.69: zeatin reductase EC 1.3.1.70: Δ14-sterol reductase EC 1.3.1.71: Δ24(241)-sterol reductase EC 1.3.1.72: Δ24-sterol reductase EC 1.3.1.73: 1,2-dihydrovomilenine reductase EC 1.3.1.74: 2-alkenal reductase [NAD(P)+] EC 1.3.1.75: 3,8-divinyl protochlorophyllide a 8-vinyl-reductase (NADPH) EC 1.3.1.76: precorrin-2 dehydrogenase EC 1.3.1.77: anthocyanidin reductase [(2R,3R)-flavan-3-ol-forming] EC 1.3.1.78: arogenate dehydrogenase (NADP+) EC 1.3.1.79: arogenate dehydrogenase (NAD(P)+) EC 1.3.1.80: Now classified as EC 1.3.7.12, red chlorophyll catabolite reductase EC 1.3.1.81: (+)-pulegone reductase EC 1.3.1.82: (-)-isopiperitenone reductase EC 1.3.1.83: geranylgeranyl diphosphate reductase EC 1.3.1.84: acrylyl-CoA reductase (NADPH) EC 1.3.1.85: crotonyl-CoA carboxylase/reductase EC 1.3.1.86: crotonyl-CoA reductase EC 1.3.1.87: 3-(cis-5,6-dihydroxycyclohexa-1,3-dien-1-yl)propanoate dehydrogenase EC 1.3.1.88: tRNA-dihydrouridine16/17 synthase (NAD(P)+) EC 1.3.1.89: tRNA-dihydrouridine47 synthase (NAD(P)+) EC 1.3.1.90: tRNA-dihydrouridine20a/20b synthase (NAD(P)+) EC 1.3.1.91: tRNA-dihydrouridine20 synthase (NAD(P)+) EC 1.3.1.92: artemisinic aldehyde Δ11(13)-reductase EC 1.3.1.93: very-long-chain enoyl-CoA reductase EC 1.3.1.94: polyprenol reductase EC 1.3.1.95: acrylyl-CoA reductase (NADH) EC 1.3.1.96: Botryococcus squalene synthase EC 1.3.1.97: botryococcene synthase EC 1.3.1.98: Now known to be catalyzed by two different enzymes, EC 1.3.1.122, (S)-8-oxocitronellyl enol synthase, and EC 5.5.1.34, (+)-cis,trans-nepetalactol synthase EC 1.3.1.100: chanoclavine-I aldehyde reductase EC 1.3.1.101: 2,3-bis-O-geranylgeranyl-sn-glycerol 1-phosphate reductase [NAD(P)H] EC 1.3.1.102: 2-alkenal reductase (NADP+) EC 1.3.1.103: 2-haloacrylate reductase EC 1.3.1.104: enoyl-[acyl-carrier-protein] reductase (NADPH) EC 1.3.1.105: 2-methylene-furan-3-one reductase EC 1.3.1.106: cobalt-precorrin-6A reductase EC 1.3.1.107: sanguinarine reductase EC 1.3.1.108: caffeoyl-CoA reductase EC 1.3.1.109: butanoyl-CoA dehydrogenase complex (NAD+, ferredoxin) EC 1.3.1.110: lactate dehydrogenase (NAD+,ferredoxin) EC 1.3.1.111: geranylgeranyl-bacteriochlorophyllide a reductase EC 1.3.1.112: anthocyanidin reductase [(2S)-flavan-3-ol-forming] EC 1.3.1.113: (4-alkanoyl-5-oxo-2,5-dihydrofuran-3-yl)methyl phosphate reductase EC 1.3.1.114: 3-dehydro-bile acid Δ4,6-reductase EC 1.3.1.115: 3-oxocholoyl-CoA 4-desaturase EC 1.3.1.116: 7β-hydroxy-3-oxochol-24-oyl-CoA 4-desaturase EC 1.3.1.117: hydroxycinnamoyl-CoA reductase EC 1.3.1.118: meromycolic acid enoyl-[acyl-carrier-protein] reductase EC 1.3.1.119: chlorobenzene dihydrodiol dehydrogenase EC 1.3.1.120: cyclohexane-1-carbonyl-CoA reductase NADP+) EC 1.3.1.121: 4-amino-4-deoxyprephenate dehydrogenase EC 1.3.1.122: (S)-8-oxocitronellyl enol synthase EC 1.3.1.123: 8-oxogeranial reductase EC 1.3.1.124: 2,4-dienoyl-CoA reductase [(3E)-enoyl-CoA-producing]
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.